O	0	1	A
O	2	7	phase
O	8	11	two
O	12	22	randomised
O	23	28	trial
O	29	31	of
B-intervention	32	41	neratinib
I-intervention	42	53	monotherapy
O	54	60	versus
B-control	61	70	lapatinib
I-control	71	75	plus
I-control	76	88	capecitabine
O	89	100	combination
O	101	108	therapy
O	109	111	in
O	112	120	patients
O	121	125	with
O	126	130	HER2
O	130	131	+
O	132	140	advanced
O	141	147	breast
O	148	154	cancer
O	154	155	.

O	156	159	The
O	160	166	safety
O	167	170	and
O	171	179	efficacy
O	180	182	of
O	183	192	neratinib
O	193	204	monotherapy
O	205	209	were
O	210	218	compared
O	219	223	with
O	224	228	that
O	229	231	of
O	232	241	lapatinib
O	242	246	plus
O	247	259	capecitabine
O	260	262	in
B-eligibility	263	271	patients
I-eligibility	272	276	with
I-eligibility	277	282	human
I-eligibility	283	292	epidermal
I-eligibility	293	299	growth
I-eligibility	300	306	factor
I-eligibility	307	315	receptor
I-eligibility	315	316	-
I-eligibility	316	317	2
I-eligibility	317	318	-
I-eligibility	318	326	positive
I-eligibility	327	328	(
I-eligibility	328	332	HER2
I-eligibility	332	333	+
I-eligibility	333	334	)
I-eligibility	334	335	,
I-eligibility	336	343	locally
I-eligibility	344	352	advanced
I-eligibility	352	353	/
I-eligibility	353	363	metastatic
I-eligibility	364	370	breast
I-eligibility	371	377	cancer
I-eligibility	378	381	and
I-eligibility	382	387	prior
I-eligibility	388	399	trastuzumab
I-eligibility	400	409	treatment
O	409	410	.

O	411	419	Patients
O	420	428	received
O	429	438	neratinib
O	439	442	240
O	443	445	mg
O	445	446	/
O	446	447	d
O	448	460	continuously
O	461	462	(
O	462	463	n
O	463	464	=
B-intervention-participants	464	467	117
O	467	468	)
O	469	471	or
O	472	481	lapatinib
O	482	486	1250
O	487	489	mg
O	489	490	/
O	490	491	d
O	492	504	continuously
O	505	509	plus
O	510	522	capecitabine
O	523	527	2000
O	528	530	mg
O	530	531	/
O	531	532	m
O	532	533	(
O	533	534	2
O	534	535	)
O	536	539	per
O	540	543	day
O	544	546	on
O	547	551	days
O	552	553	1
O	553	554	-
O	554	556	14
O	557	559	of
O	560	564	each
O	565	567	21
O	567	568	-
O	568	569	d
O	570	575	cycle
O	576	577	(
O	577	578	n
O	578	579	=
B-control-participants	579	582	116
O	582	583	)
O	583	584	.

O	585	588	The
O	589	596	primary
O	597	600	aim
O	601	604	was
O	605	607	to
O	608	619	demonstrate
O	620	623	non
O	623	624	-
O	624	635	inferiority
O	636	638	of
O	639	648	neratinib
O	649	652	for
B-outcome-Measure	653	664	progression
I-outcome-Measure	664	665	-
I-outcome-Measure	665	669	free
I-outcome-Measure	670	678	survival
I-outcome-Measure	679	680	(
I-outcome-Measure	680	683	PFS
I-outcome-Measure	683	684	)
O	684	685	.

O	686	689	The
B-outcome	690	693	non
I-outcome	693	694	-
I-outcome	694	705	inferiority
O	706	708	of
O	709	718	neratinib
O	719	722	was
O	723	726	not
O	727	739	demonstrated
O	740	744	when
O	745	753	compared
O	754	758	with
O	759	768	lapatinib
O	769	773	plus
O	774	786	capecitabine
O	787	788	(
O	788	794	hazard
O	795	800	ratio
O	800	801	,
O	802	803	1
O	803	804	.
O	804	806	19
O	806	807	;
O	808	810	95
O	810	811	%
O	812	822	confidence
O	823	831	interval
O	831	832	,
O	833	834	0
O	834	835	.
O	835	837	89
O	837	838	-
O	838	839	1
O	839	840	.
O	840	842	60
O	842	843	;
O	844	847	non
O	847	848	-
O	848	859	inferiority
O	860	866	margin
O	866	867	,
O	868	869	1
O	869	870	.
O	870	872	15
O	872	873	)
O	873	874	.

B-outcome	875	881	Median
I-outcome	882	885	PFS
O	886	889	for
O	890	899	neratinib
O	900	903	was
B-iv-cont-median	904	905	4
I-iv-cont-median	905	906	.
I-iv-cont-median	906	907	5
I-iv-cont-median	908	914	months
O	915	921	versus
B-cv-cont-median	922	923	6
I-cv-cont-median	923	924	.
I-cv-cont-median	924	925	8
I-cv-cont-median	926	932	months
O	933	936	for
O	937	946	lapatinib
O	947	951	plus
O	952	964	capecitabine
O	965	968	and
B-outcome	969	975	median
I-outcome	976	983	overall
I-outcome	984	992	survival
O	993	996	was
B-iv-cont-median	997	999	19
I-iv-cont-median	999	1000	.
I-iv-cont-median	1000	1001	7
I-iv-cont-median	1002	1008	months
O	1009	1015	versus
B-cv-cont-median	1016	1018	23
I-cv-cont-median	1018	1019	.
I-cv-cont-median	1019	1020	6
I-cv-cont-median	1021	1027	months
O	1027	1028	.

B-outcome	1029	1038	Objective
I-outcome	1039	1047	response
I-outcome	1048	1052	rate
O	1053	1054	(
O	1054	1063	neratinib
O	1063	1064	,
B-iv-bin-percent	1065	1067	29
I-iv-bin-percent	1067	1068	%
O	1069	1075	versus
O	1076	1085	lapatinib
O	1086	1090	plus
O	1091	1103	capecitabine
O	1103	1104	,
B-cv-bin-percent	1105	1107	41
I-cv-bin-percent	1107	1108	%
O	1108	1109	;
O	1110	1111	P
O	1111	1112	=
O	1112	1113	0
O	1113	1114	.
O	1114	1117	067
O	1117	1118	)
O	1119	1122	and
B-outcome	1123	1131	clinical
I-outcome	1132	1139	benefit
I-outcome	1140	1144	rate
O	1145	1146	(
B-iv-bin-percent	1146	1148	44
I-iv-bin-percent	1148	1149	%
O	1150	1156	versus
B-cv-bin-percent	1157	1159	64
I-cv-bin-percent	1159	1160	%
O	1160	1161	;
O	1162	1163	P
O	1163	1164	=
O	1164	1165	0
O	1165	1166	.
O	1166	1169	003
O	1169	1170	)
O	1171	1175	were
O	1176	1181	lower
O	1182	1185	for
O	1186	1189	the
O	1190	1199	neratinib
O	1200	1203	arm
O	1204	1207	but
O	1208	1218	consistent
O	1219	1223	with
O	1224	1234	previously
O	1235	1243	reported
O	1244	1251	results
O	1251	1252	.

O	1253	1255	In
O	1256	1260	both
O	1261	1270	treatment
O	1271	1275	arms
O	1275	1276	,
B-outcome	1277	1286	diarrhoea
O	1287	1290	was
O	1291	1294	the
O	1295	1299	most
O	1300	1310	frequently
O	1311	1319	reported
O	1320	1329	treatment
O	1329	1330	-
O	1330	1337	related
O	1338	1345	adverse
O	1346	1351	event
O	1352	1354	of
O	1355	1358	any
O	1359	1364	grade
O	1365	1366	(
O	1366	1375	neratinib
O	1375	1376	,
B-iv-bin-percent	1377	1379	85
I-iv-bin-percent	1379	1380	%
O	1381	1387	versus
O	1388	1397	lapatinib
O	1398	1402	plus
O	1403	1415	capecitabine
O	1415	1416	,
B-cv-bin-percent	1417	1419	68
I-cv-bin-percent	1419	1420	%
O	1420	1421	;
O	1422	1423	P
O	1423	1424	=
O	1424	1425	0
O	1425	1426	.
O	1426	1429	002
O	1429	1430	)
O	1431	1434	and
O	1435	1437	of
B-outcome	1438	1443	grade
I-outcome	1444	1445	3
I-outcome	1445	1446	/
I-outcome	1446	1447	4
O	1448	1449	(
B-iv-bin-percent	1449	1451	28
I-iv-bin-percent	1451	1452	%
O	1453	1459	versus
B-cv-bin-percent	1460	1462	10
I-cv-bin-percent	1462	1463	%
O	1463	1464	;
O	1465	1466	P
O	1466	1467	<
O	1467	1468	0
O	1468	1469	.
O	1469	1472	001
O	1472	1473	)
O	1473	1474	,
O	1475	1478	but
O	1479	1482	was
O	1483	1492	typically
O	1493	1500	managed
O	1501	1505	with
O	1506	1517	concomitant
O	1518	1522	anti
O	1522	1523	-
O	1523	1533	diarrhoeal
O	1534	1544	medication
O	1545	1548	and
O	1548	1549	/
O	1549	1551	or
O	1552	1557	study
O	1558	1567	treatment
O	1568	1580	modification
O	1580	1581	.

O	1582	1593	Importantly
O	1593	1594	,
O	1595	1604	neratinib
O	1605	1608	had
O	1609	1611	no
O	1612	1623	significant
B-outcome	1624	1628	skin
I-outcome	1629	1637	toxicity
O	1637	1638	.

O	1639	1642	The
O	1643	1650	results
O	1651	1654	are
O	1655	1665	considered
O	1666	1668	as
O	1669	1681	inconclusive
O	1682	1687	since
O	1688	1695	neither
O	1696	1707	inferiority
O	1708	1711	nor
O	1712	1715	non
O	1715	1716	-
O	1716	1727	inferiority
O	1728	1730	of
O	1731	1740	treatment
O	1741	1745	with
O	1746	1755	neratinib
O	1756	1762	versus
O	1763	1772	lapatinib
O	1773	1777	plus
O	1778	1790	capecitabine
O	1791	1796	could
O	1797	1799	be
O	1800	1812	demonstrated
O	1812	1813	.

O	1814	1817	The
O	1818	1823	study
O	1824	1833	confirmed
O	1834	1842	relevant
O	1843	1849	single
O	1849	1850	-
O	1850	1855	agent
O	1856	1864	clinical
O	1865	1873	activity
O	1874	1877	and
O	1878	1888	acceptable
O	1889	1896	overall
O	1897	1909	tolerability
O	1910	1912	of
O	1913	1922	neratinib
O	1923	1925	in
O	1926	1934	patients
O	1935	1939	with
O	1940	1949	recurrent
O	1950	1954	HER2
O	1954	1955	+
O	1956	1964	advanced
O	1965	1971	breast
O	1972	1978	cancer
O	1978	1979	.
